Kimberly Feder
Optometrist · Fort Myers, FLNPI 1073551735
Payments from drug & device makers
Across 265 payments — averaging $52.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$3K
- Alcon$3K
- Bausch & Lomb Americas Inc.$1K
- AbbVie$1K
- Sun Pharmaceutical Industries Inc.$1K
- Tarsus Pharmaceuticals, Inc.$978
- plus $4K from 19 others
What the payments were for
- Travel & lodging$1,1638%
- Food & beverage$12,72592%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 24 | $2,803 |
| Alcon | 42 | $2,644 |
| Bausch & Lomb Americas Inc. | 35 | $1,449 |
| AbbVie(2 entities) | 36 | $1,151 |
| Sun Pharmaceutical Industries Inc. | 39 | $1,099 |
| Tarsus Pharmaceuticals, Inc. | 14 | $978 |
| Amgen(2 entities) | 19 | $884 |
| Dompe US, Inc. | 9 | $549 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $500 |
| Coopervision Inc. | 12 | $492 |
| Johnson & Johnson Vision Care, Inc. | 4 | $299 |
| Kala Pharmaceuticals, Inc. | 4 | $148 |
| Sight Sciences, Inc. | 2 | $145 |
| Rxsight Inc | 1 | $119 |
| Maculogix, Inc. | 1 | $115 |
| Ocular Therapeutix, Inc. | 1 | $109 |
| Oyster Point Pharma, Inc. | 3 | $103 |
| Novartis | 4 | $99 |
| Staar Surgical Company | 2 | $84 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $36 |
| Harrow Eye, LLC | 2 | $36 |
| Aerie Pharmaceuticals, Inc. | 1 | $20 |
| Omeros Corporation | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| ABB Con-cise Optical Group LLC | 2 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOTAL30$784
- MIEBO$774
- TEPEZZA$737
- Prokera$703
- XDEMVY$661
- XIIDRA$649
- Precision7$491
- DURYSTA$374
- CEQUA$350
- BTOD$292
- ULTRA$292
- Oxervate$246
- LUMIGAN$234
- OMNI(R) SURGICAL SYSTEM (US)$128
- TRYPTYR$126
- Acuvue$125
- RESTASIS MULTIDOSE$125
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$119
- AdaptDx$115
- COMBIGAN$110
How this compares
$13,899 in reported general payments places this provider in the 95th percentile of 3,166 optometrist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 60 | $73,055 |
| XiidraLifitegrast | 29 | $50,422 |
| MieboPerfluorohexyloctane/Pf | 17 | $17,211 |
| LumiganBimatoprost | 12 | $8,067 |
| Lotemax SmLoteprednol Etabonate | 15 | $3,736 |
| Prednisolone Acetate | 38 | $1,205 |
| Brimonidine Tartrate | 12 | $794 |
| Latanoprost | 50 | $569 |
| Ketorolac Tromethamine | 13 | $518 |
| MoxifloxacinMoxifloxacin Hcl | 24 | $388 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 33 | $310 |
| ErythromycinErythromycin Base | 25 | $246 |
| Timolol Maleate | 22 | $118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $1,151 | $81,12272 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $1,449 | $67,63446 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $500 | $3,73615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,166 optometrist providers in Florida.
Other optometrist in Fort Myers
- Michael KynnJacksonville$4.5M
- Christine HalodaJacksonville$3.1M
- Bradley GieddWinter Park$2.5M
- Christopher PearsonLongwood$2.5M
- Mark PerryOrlando$1.6M
- Bryan StamJacksonville Beach$1M
- Oksana SovaJacksonville$841K
- James HoffmanOrange Park$795K
- April JasperWest Palm Beach$781K
- Jerry RobbenSt Augustine$663K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.